This study investigated the association between blood transfusions (BT) and inflammation after surgery on the outcomes of patients with colorectal cancer. Researchers suggested that blood transfusion was associated with poorer outcomes for these patients.

This study compared the effectiveness of open and non-invasive surgery (NIS) in the treatment of rectal cancer. Researchers suggested that open surgery is associated with improved complete tumor removal, while NIS is associated with fewer complications.

This study investigated whether treatment with encorafenib (Braftovi), binimetinib (Mektovi), and cetuximab (Erbitux) combined would increase survival in advanced colorectal cancer (CRC). Researchers suggested that this combined therapy increases the survival of patients with metastatic (spread to other parts of the body) CRC.

This study investigated the role of oxaliplatin (Eloxatin) in treating patients with rectal cancer after surgery. Researchers suggested that this drug may be a good option in the treatment of rectal cancer.  

This study investigated the effectiveness of physical activity (PA) on the outcomes of patients with advanced colorectal cancer. Researchers suggested that regular PA is associated with better outcomes for these patients.

This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with colorectal cancer receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients.

This phase 1/2 trial is examining the effectiveness of standard therapy alone or combined with new drugs as first line treatment for advanced colorectal cancer. The main outcome to be measured will be safety and tumor response to the treatment. 

This study investigated the effectiveness and safety of increasing doses of regorafenib (Stivarga) doses in patients with advanced colorectal cancer. Researchers suggested that this method with increasing doses should be used to assess the optimal dose for each patient.

This phase 1b trial is examining the effectiveness and safety of a vaccine treatment, ATP128, in the treatment of advanced colorectal cancer. The main outcome to be measured is the tumor response to the treatment and treatment toxicity. This trial is being conducted in Arizona and California, US.

This phase 1/2 trial is examining the effectiveness of treatment with GB1275 alone or in combination with immunotherapy in patients with advanced solid tumors such as colorectal cancer. The main outcome to be measured will be dose toxicity and tumor response to the treatment. This study is being conducted in Tennessee and Texas, US.